- Philadelphia and Bucks County Recovery Houses
- In The Rooms
- Recovery Centers America PA
- Day Break Solutions Treatment Pa.
- My Recovery Online meetings
- Recovery Connections You Tube Channel
- Christian Rehab Center locator
- Jade Recovery Veterans Support
- HELP FOR TEENS
- Pregnancy Help Choice One
- ARS All Resource Solutions
- Pro Act Philly
- Rehab Help
- Northbound Veterans Help
Thursday, December 4, 2014
Pharmacies Stock “Meth-Resistant” Cold Medications – and See Drop in Community Meth Labs
December 3rd, 2014/
In several states across the country, lawmakers are gearing up to debate whether pseudoephedrine (PSE), an ingredient in cold medications like Sudafed, should require a prescription. While PSE has long been an ingredient that consumers have relied on to treat nasal congestion, it is also one of the main ingredients used to make methamphetamine (meth).
According to data from the Substance Abuse and Mental Health Administration, over 100,000 more people used meth in 2013 than in the previous year. Meth is a highly addictive illegal drug that can be produced relatively easily by combining household chemical ingredients with these common over-the-counter cold medicines. The impact of meth use and production extends far beyond those who use and abuse the drug, spurring unintended “collateral damage” for the surrounding communities including fires caused by lab explosions, the cost of foster care for children whose parents are drug users and toxic waste from the chemicals used to make the dangerous drug.
Advocates of the prescription-only legislation believe that it will be more difficult for meth producers to get their hands on PSE products, which would in-turn decrease meth-related crime and lab incidents. However, others argue that requiring a prescription for these cold medications would punish innocent cold and allergy sufferers, who would sacrifice extra time and money for doctors’ visits to acquire the prescription.
There is a trend developing locally that is impacting meth production in a positive way, all without enacting sweeping law changes. Many pharmacies across the country are taking the issue into their own hands by making a change in the type of PSE products they sell. Their relatively simple switch to “meth-resistant” pseudoephedrine products has started to drive down illegitimate PSE sales and reduce meth labs in areas of the country. Over the past two years, nearly 30,000 pharmacies nationwide have started stocking this new type of pseudoephedrine, which includes technology that makes it harder to convert the cold medicine into meth.
Pharmacies in West Virginia – including CVS, Rite Aid and the local Fruth Pharmacy chain – have taken it one step further and have done away entirely with traditional single-ingredient PSE products and replaced them with “meth-resistant” formulations. According to local reports, the state has seen a 30 percent drop in PSE sales since the pharmacies stopped carrying Sudafed and its store-brand generic equivalents. In nearby Tennessee, two counties in a particularly meth-ridden area implemented a similar program and saw a75 percent drop in PSE sales and more than an 85 percent decrease in meth labs.
Nexafed® has been clinically proven by FDA standards to treat nasal congestion as effectively as standard PSE, while also reducing the amount of pseudoephedrine that can be converted during the meth-making process. Impede®, the unique meth-resistant technology in Nexafed, works by trapping the PSE in a thick gel that forms when the medicine tablet is placed in water or other solvents, which is generally how manufacturers extract PSE from cold medications like Sudafed. The product’s unique meth-deterring technology renders it essentially useless for meth producers who get a significantly lower yield of meth from the product to make it worth their time.
“Ultimately, meth-deterrent PSE formulations give peace of mind to the pharmacists who want to make sure effective PSE is in the hands of the consumers who need it, while making it much harder for meth cooks to get their supply of a key meth making ingredient,” said Bob Jones, president of Acura Pharmaceuticals, the makers of Nexafed. “We are thrilled with the success that’s been achieved in Tennessee and West Virginia, but know that more can and should be done by other states and big pharmacy retailers to reduce meth production and make the switch to meth-resistant PSE products.”
While these cold-medications won’t solve the broader meth addiction and abuse problem, data show they are making a difference in reducing illegitimate PSE sales and domestic meth production. This means fewer fires, less toxic waste, lower costs for cleanup and foster care – all desirable outcomes without requiring legislation. For pharmacies, stocking meth-resistant cold medications is a simple way to provide customers with the medicine they have always relied on without requiring them to visit the doctor every time they have a cold. And this switch keeps meth producers looking elsewhere.
Acura Pharmaceuticals provides an unrestricted educational grant to The Meth Project, a large-scale prevention program aimed at reducing meth use through public service messaging, public policy, and community outreach. Visit www.methproject.org for more information and find out how to help Join the Fight Against Meth on Facebook.